CBOA
BCRX icon

Commonwealth Bank of Australia’s BioCryst Pharmaceuticals BCRX Stock Holding History

Commonwealth Bank of Australia’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,550
Closed -$323K – 814
2014
Q1 		$323K Buy
30,550
+900
+3% +$9.6K ﹤0.01% 1141
2013
Q4 		$225K Buy
29,650
+15,650
+112% +$99.1K ﹤0.01% 1165
2013
Q3 		$102K Buy
+14,000
New +$71K ﹤0.01% 1186

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Commonwealth Bank of Australia's BCRX Position: Q2 2014 in Review

Commonwealth Bank of Australia sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2014, closing a stake of 30,550 shares — an estimated $323K sold.

Commonwealth Bank of Australia first reported a position in BCRX in Q3 2013 and held it in 3 quarters. The position peaked at $323K in Q1 2014. 103 funds tracked by Wall St. Rank hold BCRX as of Q2 2014.

  • Commonwealth Bank of Australia reported no remaining BioCryst Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Commonwealth Bank of Australia sold 30,550 BioCryst Pharmaceuticals shares in Q2 2014, an estimated $323K.
  • Commonwealth Bank of Australia first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Commonwealth Bank of Australia's BioCryst Pharmaceuticals position peaked at $323K in Q1 2014.
  • 103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2014.

Based on Commonwealth Bank of Australia's 13F filing for Q2 2014, filed 11 Aug 2014.